"Tackling the COVID-19 pandemic requires both prevention via vaccine and targeted treatment for those who contract the virus," Pfizer's Chief Scientific Officer Mikael Dolsten said on Tuesday.
Dr. Yvelice Villaman-Bencosme, 64, was sentenced to 63 months behind bars in federal court on Monday.
Trump's numerous vows to have a COVID-19 vaccine before Election Day have been criticized by physicians who said the unfulfilled campaign promises must stop.
The investigation comes amid fears the authorisation of COVID-19 vaccines may be politicized.
Unlike the other vaccine candidates that require two doses, the Johnson & Johnson vaccine is a single-dose, which may make it easier to distribute.
Dozens of vaccines for COVID-19 are currently in human clinical trials, with a small number already approved for limited use— however, none have reached the final stage of research proving they are safe and effective.
Phase 3 trials for AstraZeneca's COVID-19 vaccine candidate were paused Tuesday due to a "potentially unexplained illness in one of the trials."
Moderna's two-dose vaccine candidate is believed to be "generally safe and well-tolerated" and potentially effective regardless of age, according to new data released by the company on Wednesday.
"The more vaccines we have, the better for the whole of humanity," the director of Russia's sovereign wealth fund said.
"The Russians, to my knowledge and I'm pretty sure I'm correct, have not been studying this intensively in very large, randomized, placebo-controlled trials," Fauci said during a livestream on Wedneday.
Plasma therapy has long been used to treat other diseases.
Two vaccine candidates that could potentially halt the spread of COVID-19 entered late-stage clinical trials on Monday.
Several Russian health officials have denied the allegation.
Early results from a study of a new potential coronavirus vaccine revealed that all participants given the vaccine produced antibodies that could prevent COVID-19.
There are at least 160 potential novel coronavirus vaccines in development in the U.S., Europe, China and Australia.
The COPCOV study is a randomized, placebo-controlled trial that will enroll around 40,000 healthcare workers and other at-risk workers worldwide. It will test whether or not the drugs are effective in preventing COVID-19 in those who do not yet have it.
"Key results will be obtained in less than two months, but the trial will extend beyond that to look at long-term immune responses," said Walter Reed Army Institute of Research spokesman Samir Deshpande on Thursday.
Two Chinese companies working directly under state supervision say they will be ready to mass produce a coronavirus vaccine by as early as December 2020.
VA researchers have enrolled 200 veterans in a trial testing whether the prostate cancer drug degarelix could prove to be an effective treatment for men with COVID-19.
The National Institutes of Health have launched a placebo-controlled trial testing the safety and efficacy of hydroxychloroquine and azithromycin as a treatment for COVID-19.
Famotidine is normally used to relieve the symptoms of acid reflux and heartburn, which it does by reducing the amount of acid in the stomach.
Multiple clinical trials using the experimental Ebola drug remdesivir to treat COVID-19 are currently in progress.
The Japanese anti-viral drug is said to interfere with the virus replication process, which may help combat the COVID-19 virus.
A Phase II clinical trial has begun investigating the drug in patients with mild-to-moderate forms of the disease.
"God showed me a certain tree and certain people. We have found the cure for HIV and AIDS," Walter Magaya told followers last month.
The drug has also been eyed to treat depression and PTSD.
Researchers think this trial could be "the real beginning of gene therapy."
Data from a highly anticipated, landmark study have finally been presented.
One family has three children with a fatal, progressive genetic disease. Will the FDA approve a drug they believe has helped them?
When should cancer patients consider clinical trials? Where should they look? How should they evaluate options?